Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 96 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March New on NCI’s Websites for March 2025 MOST POPULAR FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma June 11, 2024 Can Using a Microwave Cause Cancer? March 25, 2021 ESMO Gynaecological Cancers Congress 2024, 20-22 June, Florence, Italy June 6, 2024 What’s happened to cancer clinical trials during the COVID-19 pandemic? November 4, 2020 Load more HOT NEWS With 3 Years Minimum Follow-Up, Nivolumab Plus Ipilimumab Continues to Provide... Cancer Moonshot℠ Workshop Highlights Recent Research Advances “Things Are Shrinking” Says Olivia Newton-John About Her Stage IV Breast... How Pelvic Floor Therapy Can Help People With Prostate Cancer and...
